Respiration Rate Monitoring in COPD Patients

Overview

Assess the feasibility of using remote respiration rate monitoring as a component of home care, how respiration rate data may be used in combination with other data to potentially improve response to symptoms, and to generate data to inform the endpoints and effect sizes of future studies.

Full Title of Study: “Assessment of the Temporal Changes in Nightly Respiration Rate in Combination With a Daily Symptom Reporting Application for Facilitating Early Treatment of Symptoms in COPD Patients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 26, 2017

Detailed Description

The research question is whether monitoring of respiration rates and variability can be helpful in management of COPD patients in conjunction with or separately from self-reported symptom scores using the COPD Co-PILOT application. Current techniques (such as patient's self-reported symptoms) have limited sensitivity and specificity with regard to predicting decompensation. Measurement of respiration parameters and the variability of the parameters may detect worsening COPD. Changes in respiration patterns may occur sufficiently far in advance of decompensation (e.g. >5 days prior to patient symptoms) such that it would allow an opportunity for earlier intervention with medical assessment and current therapeutic approaches.

The specific primary aim includes evaluation of the correlation of respiration rate parameters to indicators of healthcare utilization including drug changes, office or ER visits, hospitalization, or other clinical interventions. Secondary aims include evaluation of (i) the sensitivity and specificity of respiration rate monitoring results to predict COPD worsening requiring medical intervention, (ii) the sensitivity and specificity of respiration rate monitoring results in conjunction with COPD Co-PILOT scores or components to predict COPD worsening requiring medical intervention, and the correlation of respiration rate parameters to episode duration as defined by number of days from COPD Co-PILOT Score >1 to resolution (COPD Co-PILOT Score <1 for 7 consecutive days).

Interventions

  • Device: Reassure Non-Contact Respiration Monitor
    • Reassure Respiration Monitor uses very low power radio waves to detect respiratory movements of a person while asleep in bed – without physical contact with the individual. Algorithms analyze the respiratory movement signals and extract information about respiration rate and variability. This data is uploaded to a secure cloud infrastructure for storage.

Arms, Groups and Cohorts

  • Experimental: Respiration rate monitoring
    • Reassure Non-Contact Respiration Monitor

Clinical Trial Outcome Measures

Primary Measures

  • Correlation of Respiration Rate to Indicators of Healthcare Utilization
    • Time Frame: 12 weeks
    • Indicators of healthcare utilization include change in medications for COPD, number of office or ER visits, number of hospitalizations.

Secondary Measures

  • Sensitivity and Specificity of Respiration Rate to Predict COPD Worsening
    • Time Frame: Baseline to 12 weeks
  • Sensitivity and Specificity of Respiration Rate in Conjunction with COPD Co-PILOT Scores to Predict COPD Worsening
    • Time Frame: 12 weeks
  • Correlation of Respiration Rate to COPD Episode Duration
    • Time Frame: 12 weeks
    • Episode duration is defined by number of days from COPD Co-PILOT Score >1 to resolution (COPD Co-PILOT Score <1 for 7 consecutive days)

Participating in This Clinical Trial

Inclusion Criteria

  • Males or females age ≥35 years old
  • Documented diagnosis of moderate to very severe COPD (GOLD Level II-IV)
  • Weight ≥35 kg
  • Currently using the COPD Co-PILOT application (at least 3 months with 70% compliance)
  • Must be able to read and understand English and consent for themselves

Exclusion Criteria

  • Currently using any form of non-invasive positive airway pressure ventilation
  • Diagnosis of significant heart failure (NYHA Class III or IV)
  • Cognitive impairment (determined by physician) that will make it hard to follow instructions regarding device usage
  • BMI ≥45.5
  • Residing in hospice care, Skilled Nursing Facilities or Long Term Acute Care facilities
  • Currently using a wearable drug infusion pump to deliver medication
  • Planned procedures at time of enrollment that will occur within timeframe of study and require hospitalization etc.
  • Declines to participate at any time.
  • In the opinion of the Investigator, may be non-compliant with study schedules or procedures
  • No cellular coverage at their primary residence

Gender Eligibility: All

Minimum Age: 35 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • ResMed
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Gerard Criner, MD, Principal Investigator, Temple University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.